Clinical Trial SuccessThe company's late stage clinical asset, ALXN1840, for Wilson disease has shown promising results, achieving its primary efficacy endpoint in a phase III clinical trial.
Innovative TherapiesMonopar Therapeutics' development of a uPAR-targeted radioligand therapy in oncology represents additional upside potential in their business model.
Market PotentialThe total addressable market for ALXN1840 could reach $420M in the U.S. alone, based on an estimate of 10,000-12,000 WD patients in the U.S.